Lixumistat

Lixumistat (IM156) is a novel biguanide mitochondrial protein complex 1 inhibitor of oxidative phosphorylation (OXPHOS) with anti-tumor activity. Lixumistat regulates OXPHOS to attenuate mitochondrial metabolic reprogramming and inhibit lung fibrosis. Lixumistat also suppresses B-cell activation to alleviate systemic lupus erythematosus[1][5].

Product Specifications

CAS Number

[1422365-93-2]

Product Name Alternative

IM156 (free base) ; HL156A (free base) ; HL271 (free base)

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Mitochondrial Metabolism

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/lixumistat.html

Concentration

10mM

Purity

99.33

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

N=C(N1CCCC1)NC(NC2=CC=C(OC(F)(F)F)C=C2)=N

Molecular Formula

C13H16F3N5O

Molecular Weight

315.29

Precautions

H302, H315, H319, H335

References & Citations

[1]Willette RN, et al. Modulation of Oxidative Phosphorylation with IM156 Attenuates Mitochondrial Metabolic Reprogramming and Inhibits Pulmonary Fibrosis. J Pharmacol Exp Ther. 2021 Nov;379 (3) :290-300.|[2]Shim JS, et al. The oxidative phosphorylation inhibitor IM156 suppresses B-cell activation by regulating mitochondrial membrane potential and contributes to the mitigation of systemic lupus erythematosus. Kidney Int. 2023 Feb;103 (2) :343-356.